PES Drugs and Therapeutics Committee presents a statement on the Risk of Prolonged QT Interval with Gonadotropin Releasing Hormone Agonists.
A review of the current literature pertaining to the endocrine concerns of Prader Willi Syndrome and current recommendations for screening and management of these conditions.
This paper is based on an international effort that started with exploratory meetings in 2014 in both Europe and the USA, and culminated with a Consensus…
